Abre Venous Self-expanding Stent System
Medtronic Vascular, Inc. · Decision date Oct 21, 2020
What did the FDA approve?
FDA records P200026 as an original PMA application. The recorded decision is approval, dated Oct 21, 2020.
FDA approval order statement
Approval for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 21, 2020
Regulatory record facts
- Identifier
- P200026
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- Decision code
- APPR
- Decision date
- Oct 21, 2020
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, iliac vein.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200026 received
Application receipt date recorded by FDA.
P200026 · FDA decision
APPR
P200026/S019 · Related supplement
Abre Venous Self-Expanding Stent System
P200026/S020 · Related supplement
Abre Venous Self-expanding Stent System
Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Abre Venous Self-Expanding Stent SystemP200026/S019 | Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Abre Venous Self-expanding Stent SystemP200026/S020 | Medtronic Vascular, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P200026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
